GlobeNewswire by notified

Immunicum presenterar nya forskningsdata vid årsmötet för Society for Immunotherapy of Cancer (SITC)

Dela

Pressmeddelande

Stockholm, Sverige, 9 november 2021

Immunicum presenterar nya forskningsdata vid årsmötet för Society for Immunotherapy of Cancer (SITC)

Immunicum AB (publ; IMMU.ST), ett bioteknikföretag som fokuserar på svårbehandlade solida tumörer samt att förebygga återfall i cancer, tillkännagav idag att de kommer att presentera nya forskningsdata gällande sitt canceråterfallsvaccin DCP-001 på The Society för Immunotherapy of Cancer 36th Annual Meeting (SITC 2021) som hålls onsdagen den 10 till söndagen den 14 november 2021 på Walter E. Washington Convention Center i Washington, DC och digitalt.

Studien som presenteras av Satwinder Kaur Singh, Director Research vid Immunicum, visar att intradermalt injicerat DCP-001 tas upp av migrerande dendritceller i huden vilket samtidigt leder till en aktivering av dessa celler. Processen, som också äger rum i cellkulturer med monocyt-deriverade dendritceller, kan förstärkas genom att blockera CD47, vilket talar för en kombinationsrational med anti-CD47-terapier.

"De forskningsdata som presenteras vid SITC 2021 stödjer våra observationer i de kliniska studierna och belyser hur intradermal vaccination med DCP-001 leder till systemiska immunsvar mot tumörantigener",
säger Alex Karlsson-Parra, Chief Scientific Officer på Immunicum. "Studien visar också på Immunicums vetenskapliga ledarskap inom området för allogena dendritceller."

Det godkända sammandraget kommer att finnas tillgängligt på SITC:s hemsida den 9 november kl. 8.00 (EST)/ 14.00 (CET): SITC 2021 36th Annual Meeting Website

Posterdetaljer nedan:

Postertitel:
CD47 and phosphatidylserine contribute to the interaction between antigen presenting cells and the allogeneic cell-based relapse vaccine DCP-001
Sammandragets nummer: 219
Presentatör: Satwinder Kaur Singh, PhD
Undertitel: Cellular Therapies
Datum och tid: 12 november 2021, 7:00 - 20:30 EST
Lokal: hall E

Alla posters kommer att göras tillgängliga som virtuella E-posters under SITC-mötet. Dessutom kommer postern att göras tillgänglig på Immunicums webbplats efter presentationen.

FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA:

Erik Manting
Chief Executive Officer
E-mail: ir@immunicum.com

INVESTOR RELATIONS

Brendan Payne
Stern Investor Relations
Telephone: +1 212-698-8695
E-mail: brendan.payne@sternir.com

För Sverige:

Kristina Windrup Olander
Spikinc AB
Telephone: +46 8 732 8400
E-mail: ir@immunicum.com

PRESSFRÅGOR

Eva Mulder & Sophia Hergenhan
Trophic Communications
Telephone: +49 89 2388 7731
E-mail: immu@trophic.eu

OM IMMUNICUM AB (PUBL)

Immunicum är ett bioteknikbolag som fokuserar på svårbehandlade etablerade tumörer och tumöråterfall, två viktiga utmaningar inom dagens onkologi. Vi utnyttjar vår expertis inom allogen dendritcells-biologi för att utveckla en avancerad klinisk pipeline av nya off-the-shelf produkter för solida och blodburna tumörer. Baserat i Sverige och Nederländerna, Immunicum är noterat på Nasdaq Stockholm. www.immunicum.com

Bilaga

För att se det här innehållet från www.globenewswire.com måste du ge ditt medgivande sidans topp.
För att se det här innehållet från ml-eu.globenewswire.com måste du ge ditt medgivande sidans topp.

Om

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Följ GlobeNewswire by notified

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire by notified

Ultimovacs ASA: Mandatory notification of trade by primary insider29.11.2021 20:15:15 CET | Press release

Oslo, 29 November 2021, Carlos de Sousa, Chief Executive Officer and primary insider in Ultimovacs ASA, has today bought 1,000 shares in the company at a price of NOK 114.00 per share, and a closely related party has today bought 1,000 shares in the company at a price of NOK 114.00 per share. Following this transaction, Carlos de Sousa and closely related parties hold 14,056 shares and 416,035 share options in Ultimovacs ASA. This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Norwegian Securities Trading Act. Attachments 20211129 - Ultimovacs Notification of trade - KRT-1500 220211129 - Ultimovacs Notification of trade - KRT-1500 1

PRESS RELEASE: BIGBEN: 2021/22 HALF-YEAR RESULTS29.11.2021 19:24:15 CET | Press release

Bigben Press release Lesquin, 29 November 2021 18:00 hrs Unfavourable comparison basis for HY1 2021/22 : Sales: 124,2 M€ (-8,5%)Current Operating Income: 9,9 M€ (-41,6%) i.e. 8,0% of salesNet profit : 6,9 M€ (-28,6%) Adjustment of 2021/22 targets: Sales between 270 and 300 M€Current Operating Income around 24 M€ Upgraded2022/23targets: Sales between 400 and 450 M€ with a Current Operating Margin (1) >14% BIGBEN INTERACTIVE (ISIN FR0000074072) today releases its consolidated results for 1st Half Year 2021-22 (from April 1, 2021 to September 30, 2021) as approved by its Board of directors on 29 November 2021. Consolidated in M€ - IFRS09/202109/2020 ChangeSales124,2135,8-8,5%Gross margin (1) In % of Sales EBITDA (2) In % of Sales 51,4 41,4% 24,6 19,8% 57,3 42,2% 33,4 24,6%-10,3% -26,4%Current operating income EBITA In % of Sales Non recurrent items 9,9 8,0% (5,8)16,9 12,5% (2,3) -41,6% Operating income In % of Sales 4,1 3,3%14,7 10,8%-71,8%Financial result incl. Currency gain /(loss) incl

PRESS RELEASE: NACON: HALF-YEAR RESULTS 2021/2229.11.2021 18:56:58 CET | Press release

Nacon Press release Lesquin, 29 November 2021, 18:00 hrs HY 1 2021/22 impacted by an unfavourable basis comparison: Sales: 73.0 M€ (-15.7%)Current Operating Income: 8.4 M€ (-46.3%), i.e. 11,6% of salesNet profit: 3.8 M€ (-60.4%) Ajustmentof 2021/22targets: Sales between 150 and 180 M€Current Operating Income close to 20 M€ Upwardrevision of 2022/23targets: Sales between 250 and 300 M€ with a COI rate* > 20% NACON (ISIN FR0013482791) today releases its audited consolidated results for the first half of fiscal year 2021/22 (from April 1 to September 30) as approved by its Board of directors on 29 November 2021. Consolidated in M€ - IFRS09/202109/2020 ChangeSales73,086,6-15,7%Gross margin (1) In % of Sales EBITDA (2) In % of Sales 38,0 52,1% 21,4 29,3% 45,3 52,3% 30,4 35,1%-16,0% -29,7%Current operating income EBITA In % of Sales Non recurrent items (including Bonus Shares)8,4 11,6% (4,0)15,7 18,2% (1,8) -46,3% Operating result In % of Sales4,5 6,1%13,9 16,1%-67,8%Financial result Includi

Leasinvest Real Estate NV: Minutes of the Extraordinary General Meeting of 29 November 2021 – Change of Name – Corporate Governance Charter – Executive Committee29.11.2021 17:40:00 CET | Press release

LEASINVEST REAL ESTATE NV: MINUTES OF THE EXTRAORDINARY GENERAL MEETING OF 29 NOVEMBER 2021 – CHANGE OF NAME – CORPORATE GOVERNANCE CHARTER – EXECUTIVE COMMITTEE Minutes of the extraordinary general meeting of 29/11/2021 The legally required attendance quorum was achieved so the Extraordinary General Meeting (EGM) of 29/11/2021 was able to deliberate validly. All the proposed resolutions on the agenda were adopted, including the resolutions to change the name from Leasinvest Real Estate NV to Nextensa NV and to approve the updated remuneration policy. The minutes of the meeting provide a detailed summary of all proposed resolutions on the agenda and the votes casted regarding the resolutions and are available on the website (henceforth www.nextensa.eu) here https://nextensa.eu/en/investor-relations/general-meetings/ . In the votes, due consideration was given to the double voting rights that were introduced at the EGM of 19/07/2021, as a result of which registered shareholders listed i

NetAlly Releases InSites™ Intelligence for AirMapper™ Ecosystem29.11.2021 17:01:50 CET | Press release

Automated analysis of Wi-Fi site surveys allows any network professional to see and solve coverage and performance problems COLORADO SPRINGS, Colo., Nov. 29, 2021 (GLOBE NEWSWIRE) -- NetAlly, a leading innovator of Ethernet and Wi-Fi test and analysis solutions, today announced the availability of AirMapper™ InSites™ for automated analysis and visual troubleshooting of Wi-Fi networks. “InSites continues NetAlly’s mission of simplifying Wi-Fi site surveying for everyone by automating the analysis of coverage, SNR, interference, beacon overhead, and more,” says James Kahkoska, Chief Technology Officer for NetAlly. “A simple pass/fail dashboard of survey results eliminates the need for specialized expertise and time-consuming manual evaluation. With InSites, AirMapper measurements are automatically graded against configurable thresholds and allows users to directly view the specific heatmap to quickly identify any trouble areas.” With AirMapper, users of NetAlly’s EtherScope® nXG and AirC